Serious infection rate in patients who received treatment with another biological DMARD
| Overall (N = 2578) | Patients receiving any biological agent after rituximab treatment (n = 185) | Patients receiving TNF inhibitor after rituximab treatment (n = 153) | |||
| Before other biological agent | After other biological agent | Before other TNF inhibitor | After other TNF inhibitor | ||
| Total exposure, patient-years | 5013 | 186.05 | 182.31 | 150.87 | 162.41 |
| Serious infections, n | 216 | 13 | 10 | 10 | 8 |
| Serious infections/100 patient-years | 4.31 | 6.99 | 5.49 | 6.63 | 4.93 |
| 95% CI | 3.77 to 4.92 | 4.06 to 12.03 | 2.95 to 10.19 | 3.57 to 12.32 | 2.46 to 9.85 |
DMARD, disease-modifying antirheumatic drug; TNF, tumour necrosis factor.